Pluta Ryszard M, Butman John A, Schatlo Bawarjan, Johnson Dennis L, Oldfield Edward H
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1414, USA.
J Neurosurg. 2009 Nov;111(5):1001-7, 1-4. doi: 10.3171/2009.2.JNS081256.
Investigators in experimental and clinical studies have used the intrathecal route to deliver drugs to prevent or treat vasospasm. However, a clot near an artery or arteries after subarachnoid hemorrhage (SAH) may hamper distribution and limit the effects of intrathecally delivered compounds. In a primate model of right middle cerebral artery (MCA) SAH, the authors examined the distribution of Isovue-M 300 and 3% Evans blue after infusion into the cisterna magna CSF.
Ten cynomolgus monkeys were assigned to SAH and sham SAH surgery groups (5 in each group). Monkeys received CSF injections as long as 28 days after SAH and were killed 3 hours after the contrast/Evans blue injection. The authors assessed the distribution of contrast material on serial CT within 2 hours after contrast injection and during autopsy within 3 hours after Evans blue staining.
Computed tomography cisternographies showed no contrast in the vicinity of the right MCA (p < 0.05 compared with left); the distribution of contrast surrounding the entire right cerebral hemisphere was substantially reduced. Postmortem analysis demonstrated much less Evans blue staining of the right hemisphere surface compared with the left. Furthermore, the Evans blue dye did not penetrate into the right sylvian fissure, which occurred surrounding the left MCA. The authors observed the same pattern of changes and differences in contrast distribution between SAH and sham SAH animals and between the right and the left hemispheres on Days 1, 3, 7, 14, 21, and 28 after SAH.
Intrathecal drug distribution is substantially limited by SAH. Thus, when using intrathecal drug delivery after SAH, vasoactive drugs are unlikely to reach the arteries that are at the highest risk of delayed cerebral vasospasm.
实验研究和临床研究的人员已采用鞘内途径给药以预防或治疗血管痉挛。然而,蛛网膜下腔出血(SAH)后动脉附近的血凝块可能会妨碍药物分布,并限制鞘内给药化合物的效果。在右侧大脑中动脉(MCA)SAH的灵长类动物模型中,作者研究了向小脑延髓池脑脊液注入碘克沙醇-300(Isovue-M 300)和3%伊文思蓝后的分布情况。
将10只食蟹猴分为SAH手术组和假SAH手术组(每组5只)。SAH术后长达28天,猴子接受脑脊液注射,并在注入造影剂/伊文思蓝3小时后处死。作者在注入造影剂后2小时内通过连续CT评估造影剂的分布情况,并在伊文思蓝染色后3小时内尸检时进行评估。
CT脑池造影显示右侧MCA附近无造影剂(与左侧相比,p<0.05);整个右侧大脑半球周围造影剂的分布明显减少。尸检分析表明,与左侧相比,右侧半球表面的伊文思蓝染色明显减少。此外,伊文思蓝染料未渗入围绕左侧MCA的右侧外侧裂,而左侧外侧裂有染料渗入。作者在SAH后第1、3、7、14、21和28天观察到SAH动物与假SAH动物之间以及左右半球之间造影剂分布的相同变化模式和差异。
SAH会显著限制鞘内药物的分布。因此,SAH后使用鞘内给药时,血管活性药物不太可能到达发生迟发性脑血管痉挛风险最高的动脉。